Childhood Epilepsy Syndromes and First-Line Treatments
The principal childhood epilepsy syndromes require syndrome-specific treatment selection, with phenobarbital as first-line for neonatal seizures, ethosuximide for childhood absence epilepsy, valproic acid for juvenile myoclonic epilepsy, and carbamazepine or oxcarbazepine for benign focal epilepsies.
Neonatal Seizures (Birth to 28 days)
Phenobarbital remains the first-line antiseizure medication regardless of etiology (HIE, stroke, hemorrhage) 1. The evidence shows phenobarbital achieves 80% seizure control compared to only 28% with levetiracetam 1.
Treatment Algorithm for Neonatal Seizures:
First-line:
- Phenobarbital 20 mg/kg IV for most etiologies 1
- Exception: If channelopathy suspected due to family history (KCNQ2/KCNQ3 variants), use phenytoin or carbamazepine as first-line 1
Second-line (if first-line fails):
- Phenytoin or levetiracetam for HIE, stroke, or hemorrhage 1
- Sodium channel blocker (phenytoin/carbamazepine) if channelopathy suspected based on clinical or EEG features 1
- Levetiracetam preferred if cardiac disorders present 1
- Alternative options: midazolam or lidocaine 1
Critical consideration: Phenobarbital causes hypotension in 17% versus 5% with levetiracetam 1, but this does not outweigh its superior efficacy.
Important: Discontinue antiseizure medications before discharge home if acute provoked seizures have ceased and no evidence of neonatal-onset epilepsy exists, regardless of MRI or EEG abnormalities 1.
Vitamin-Responsive Seizures:
- Trial pyridoxine (vitamin B6) if clinical features suggest B6-dependent epilepsy 1
- Trial pyridoxine if seizures fail second-line therapy without identified etiology 1
Febrile Seizures (6-60 months)
Neither continuous nor intermittent anticonvulsant therapy is recommended for simple febrile seizures 2. While phenobarbital, primidone, valproic acid, and intermittent diazepam reduce recurrence, their toxicities outweigh benefits given the benign nature of simple febrile seizures and extremely low risk of developing epilepsy.
Key point: Antipyretics are ineffective for preventing febrile seizure recurrence 2.
Childhood Absence Epilepsy (4-10 years)
Ethosuximide is the first-line treatment 3. Valproic acid has equal efficacy but greater toxicity, reserved for patients with accompanying generalized tonic-clonic seizures. Lamotrigine is effective as both monotherapy and add-on therapy 3.
Avoid: Carbamazepine may worsen absence seizures 3.
Benign Childhood Epilepsy with Centrotemporal Spikes (BCECTS, 3-13 years)
Carbamazepine is first-line in the USA and Japan; valproic acid in Europe 4. Clobazam is an alternative option 4.
Treatment duration: Keep as short as possible, ideally within 2 years of initiation, without waiting for EEG normalization 4.
Treatment decision: Consider treatment after second or third seizure, not typically after first attack 4. Base decision on:
- Seizure frequency and duration
- Circadian rhythm of attacks (nocturnal vs. diurnal)
- Impact on cognitive and behavioral function
- Parental concerns about recurrence versus medication side effects
Panayiotopoulos Syndrome (3-6 years)
First-line options: valproic acid, carbamazepine, or clobazam 4.
Benign Infantile Seizures (3-20 months)
Carbamazepine is recommended for both acute and chronic treatment of seizure clusters 4.
Juvenile Absence Epilepsy (10-17 years)
Valproic acid is first-line 3. Lamotrigine is proven effective and preferred in young women of childbearing age due to VPA's teratogenicity risk 3. Combination VPA plus lamotrigine can be used if monotherapy fails 3.
Juvenile Myoclonic Epilepsy (12-18 years)
Valproic acid is traditional first-line 3. However, topiramate is increasingly used as monotherapy in clinical practice, particularly when weight loss is desirable 3. Lamotrigine is also effective 3.
Critical warning: Phenytoin and carbamazepine worsen myoclonus when used alone 3. Oxcarbazepine, vigabatrin, and gabapentin all worsen myoclonic seizures 3.
Lifelong treatment required 3.
Epilepsy with Generalized Tonic-Clonic Seizures on Awakening
Valproic acid is first-line, especially if absence or myoclonic seizures coexist 3. If only GTCs present, phenobarbital, phenytoin, or carbamazepine may be equally effective, though phenytoin and carbamazepine may unmask other seizure types 3.
Lifelong treatment required 3.
West Syndrome (Infantile Spasms, 3-12 months)
Treatment is etiology-driven 5, 6:
- Tuberous sclerosis: Vigabatrin first-line 5
- Cryptogenic (no identified cause): ACTH (adrenocorticotropic hormone) first-line 5
- Severe symptomatic etiology (non-tuberous sclerosis): Zonisamide first-line 5
Evidence shows hormonal treatments (ACTH, prednisolone) are preferred over vigabatrin for most cases 6, as resolution of hypsarrhythmia correlates with improved cognitive outcomes 6.
Lennox-Gastaut Syndrome (1-8 years)
First-line: zonisamide or topiramate 5. Ketogenic diet shows efficacy for drug-resistant cases 6. Felbamate is effective but carries risk of fatal adverse effects 6.
Important: Unlike West syndrome, frequent interictal discharges do not drive treatment decisions in Lennox-Gastaut syndrome 6.
Doose Syndrome (Myoclonic-Astatic Epilepsy, 1-5 years)
Ketogenic diet has demonstrated particular success 6. Valproic acid and lamotrigine are pharmacologic options.
Dravet Syndrome (Infancy onset)
Ketogenic diet is highly effective 6. Avoid sodium channel blockers (carbamazepine, phenytoin, lamotrigine) as they worsen seizures. Stiripentol, valproic acid, and clobazam are preferred medications.
Common Pitfalls to Avoid
- Never use carbamazepine for absence seizures or myoclonic epilepsies - it worsens these seizure types 3
- Avoid sodium channel blockers in Dravet syndrome - they exacerbate seizures
- Do not continue neonatal antiseizure medications indefinitely - discontinue before discharge if acute provoked seizures have resolved 1
- Do not treat simple febrile seizures with chronic anticonvulsants - risks outweigh benefits 2
- Consider valproic acid teratogenicity in adolescent females - use lamotrigine or topiramate instead 3
- Do not delay epilepsy surgery evaluation in drug-resistant cases - particularly those with structural lesions 6